Drug Trial Radar · NCT05460429
Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus
Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
37,920
Planned (sponsor's estimate)
Start
Jul 30, 2022
Primary completion
Mar 15, 2023
Study completion May 15, 2023
Sponsor
- Lead sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.
Conditions
- Varicella
Interventions
Live attenuated varicella vaccineBiological
The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
Primary outcomes
What the sponsor says the trial is designed to measure.
- GMT of varicella antibody in children aged 1-6 yearsTime frame: 30 days after vaccination
- GMT of varicella antibody in healthy people aged 0-59 yearsTime frame: 30 days after vaccination
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Laian Center for Disease Control and Prevention
Chuzhou, Anhui, China · Recruiting
Liandu District Center for Disease Control and Prevention
Lishui, Zhejiang, China · Recruiting
Jiangshan Center for Disease Control and Prevention
Quzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.